2019-11-04 07:28:08 | Natera price target raised to $32 from $27 at JPMorganJPMorgan analyst Tycho Peterson raised his price target for Natera to $32 from $27 after completing a survey on the U.S. kidney transplant rejection monitoring market. He says that given the recent excitement around liquid biopsy and Natera's Signatera test for recurrence monitoring, he now believes Prospera is an underappreciated opportunity for the company in investor estimates. Peterson keeps a Neutral rating on Natera shares. | |
---|---|---|
![]() ![]()
|
| | |
| ||
| ||
| ||
|
| ||
| ||
| ||
| ||
|
| ||
| ||
, |
| |
| | |
| |
| ||
| | |
| ||
| | |
|
| ||
| | |
| ||
| ||
|